Crossmark

Seroma control in axillary lymphadenectomy with Glubran 2® without drain. Multicenter, prospective, randomized, clinical trial. GALA-ND study (Glubran, Axillary Lymphadenectomy, Ambulatory, No Drain)

Crossref DOI link: https://doi.org/10.1186/s13063-023-07840-w

Published Online: 2024-02-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

López Gordo, Sandra http://orcid.org/0000-0001-9558-0041
Ruiz-Edo, Neus

Fernández-Planas, Maria Teresa

Viscaya-Martín, Sara

Serra-Serra, Cristina

,

Buqueras, Carmen

Recaj, Mireia

Guerrero-López, Raul

Blay-Aulina, Lidia

Aparicio-Rodriguez, Oscar

Cusiné, Laura

Mira, Xavier

Clos, Montserrat

Alonso, Immaculada

Cortés Prados, Jairo

Espinoza Villalobos, Sofía

Vallejo-Barnosell, Elena

Espinoza-Villalobos, A. S.

Jimenez, Marta

Carrasquer-Puyal, Aurora

Holub, Priscila Giselle

Cases Baldo, Maria José

Garcia de Castro R, E.

Herrador Garcia, Inmaculada

Esposito, Emanuela

Garcia de Castro Rubio, E.

Gonzalez Duaigues, Marta Lourdes
Funding

Funding for this research was provided by:

Asociación Española de cirujanos

Cardiolinc
License Information

Text and Data Mining valid from 2024-02-22

Version of Record valid from 2024-02-22
More Information

Article History

Received: 19 January 2023

Accepted: 30 November 2023

First Online: 22 February 2024

Declarations

:

: The study was approved by the Ethics Committee of the coordinating center (Health Consortium Maresme, Mataró Hospital) on February 2022, code CEIm 11/22. The trial is registered at ClinicalTrials.gov registry (NCT NCT05280353).The trial is also registered in NEOPs (investigacions clínicas con productos sanitarios con marcado CE).

: Informed consent materials will be available from the corresponding author on request.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below